FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
About | Sample | Privacy

Pozen shares sink on latest Trexima delay

Pozen stock took a painful dive this morning after GlaxoSmithKline announced that their two-in-one migraine drug Trexima would be delayed yet again--this time to satisfy FDA demands for more information on evidence of genotoxicity seen in a preclinical study. That genotoxicity was seen in Trexima, but was not apparent when the two compounds used in Trexima were studied alone. That was bitter news for investors, who were hoping that the second approvable letter from the FDA--the first arrived more than a year ago--would be the charm. They drove down Pozen's value by close to half. Researchers say they'll shoot for an early meeting with the FDA to better determine how to proceed.

- check out the release
- here's the AP report on Pozen

related Articles:
FDA buoys Pozen, accepts of amended response. Report
Pozen files NDA for new migraine treatment. Report
Pozen shares sink on new demand for data. Report
Pozen shares soar on rich pain med deal. Report

More stories about FDA   GlaxoSmithKline   preclinical   Pozen   FDA approval & regulation   Biotech company news   Drug Discovery   Clinical Trials  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 70 + 26?
To combat spam, please solve the math question above.